Keywords: Pozen, Vimovo, European Patent Office, PPIs, NSAID

European Patent Office maintains Pozen's PA/Vimovo patent

Article | 12 March 2013

Print This

US drug firm Pozen (Nasdaq: POZN) says that the Opposition Division of the European Patent Office has maintained the granted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in